Compare Gilead Sciences, Inc. (GILD) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Schwab US Large Cap Growth ETF — how do they compare? Gilead Sciences, Inc. trades at $132.99 (market cap $163.51B), while Schwab US Large Cap Growth ETF trades at $34.84. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Schwab US Large Cap Growth ETF pays none, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | SCHG | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $35.30 |
52-Week Low | $108.22 | $28.10 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SCHG trades at $34.75, up 0.49% with a bullish technical signal from moving averages but mixed oscillators. The ETF provides concentrated exposure to large-cap growth stocks, particularly in technology and AI sectors, with top holdings including Nvidia, Apple, and Microsoft. Recent news highlights strong institutional interest and positioning for AI-driven growth, though concerns exist about high concentration risk and premium valuations.
Outlook remains positive given AI investment tailwinds and strong institutional flows, but investors face risks from sector concentration and potential valuation compression if growth expectations disappoint. The ETF's low-cost structure and focus on innovation leaders offer long-term growth potential despite near-term volatility concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
